{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:24:48Z","timestamp":1784071488995,"version":"3.55.0"},"reference-count":16,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Pagoclone is a cyclopyrrolone that is believed to act as a partial agonist at the \u03b3-aminobutyric acid (GABA) A\/benzodiazepine (BDZ) receptor. In theory, such partial agonists should be anxiolytic but lack the adverse side-effects of sedation, tolerance and withdrawal associated with full GABA-A\/BDZ agonists. The objective of the randomized double-blind crossover study was to assess whether pagoclone was an effective anti-panic agent and also to assess its side-effect profile. Patients recruited had a diagnosis of Panic Disorder (DSM-IV) with at least one panic attack per week. Following a 2-week screening period, patients entered a 6-week trial consisting of two 2-week treatment periods, each followed by a 1-week washout. Patients were randomly assigned to receive either pagoclone 0.1 mg t.d.s. or placebo on their first treatment period and the converse on their second. The primary measure was daily panic attack dairy. Fourteen patients completed the study, the mean number of panic attacks during screening was 5.8 \u00b1 0.8 (SEM), this fell to 3.6 \u00b1 0.5 during treatment with pagoclone (p = 0.05) and 4.3 \u00b1 0.8 with placebo (p = 0.14). There was no significant difference on direct comparison of pagoclone with placebo or in any of the secondary measures (including Rickels withdrawal scale) or the adverse event profiles. The study provides preliminary evidence that pagoclone has anxiolytic properties in the absence of typical BDZ side-effects. This is consistent with its theoretical mode of action as a partial agonist at the GABAA\/BDZ receptor.<\/jats:p>","DOI":"10.1177\/026988110101500312","type":"journal-article","created":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T19:04:54Z","timestamp":1238612694000},"page":"205-208","source":"Crossref","is-referenced-by-count":21,"title":["Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder"],"prefix":"10.1177","volume":"15","author":[{"given":"J. J.","family":"Sandford","sequence":"first","affiliation":[{"name":"Psychopharmacology Unit, School of Medical Sciences, University of Bristol, University Walk, Bristol BS8 1TD, UK;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Forshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Argyropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rich","sequence":"additional","affiliation":[{"name":"Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J.","family":"D'Orlando","sequence":"additional","affiliation":[{"name":"Addiction Therapies Inc., Wayland, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Gammans","sequence":"additional","affiliation":[{"name":"Incara Pharmaceuticals Inc., Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Nutt","sequence":"additional","affiliation":[{"name":"Psychopharmacology Unit, School of Medical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2001,5,1]]},"reference":[{"key":"atypb1","volume-title":"Benzodiazepine dependence, toxicity and abuse (Task Force Recommendations)","author":"American Psychiatric Association","year":"1990"},{"key":"atypb2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994","edition":"4"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1991.tb03097.x"},{"issue":"2","key":"atypb4","first-page":"171","volume":"27","author":"Ballenger J C","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"atypb5","first-page":"193","volume-title":"Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach","author":"Chevalier J F","year":"1993"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(83)90043-X"},{"key":"atypb7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0022-3565(25)39337-7","volume":"266","author":"Doble A","year":"1993","journal-title":"J Pharmacol Exp Therapeut"},{"key":"atypb8","first-page":"183","volume-title":"Imidazopyridines in anxiety disorders: a novel experimental and therapeutic approach","author":"Legris P","year":"1993"},{"key":"atypb9","volume-title":"Abstract for the XIII CINP","author":"Lingford-Hughes A","year":"2000"},{"key":"atypb10","volume-title":"A phase 1 double blind, parallel group, placebo-controlled tolerability and pharmacokinetic study of IP-456 administered as repeated doses (3 doses\/day) to healthy male volunteers (Protocol IP 456\u2013001)","author":"Mant T G K","year":"1995"},{"key":"atypb11","volume-title":"A phase 1 double blind, paralle.l group, placebo-controlled tolerability and pharmacokinetic study of RP 62955 administered as a single rising oral dose (from 0.02\u20132 mg) to healthy male volunteers (Protocol NGB 101)","author":"Mant T G K","year":"1996"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.283.6292.643"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199401040-00007"},{"key":"atypb14","first-page":"93","volume":"22","author":"Rickels K","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(00)00082-6"},{"key":"atypb16","volume-title":"Double-blind placebo-controlled tolerability study of RP 59037 in 12 healthy volunteers after single sequential increasing oral doses of 0.2 mg, 0.4 mg, 1 mg, 1.6 mg, 3 mg, 5 mg, and possible intermediary doses (Protocol CY1002)","author":"Truffinet P H","year":"1995"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988110101500312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/026988110101500312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:08:20Z","timestamp":1777507700000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/026988110101500312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1177\/026988110101500312"],"URL":"https:\/\/doi.org\/10.1177\/026988110101500312","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,5]]}}}